4-乙酰氨基苯酚钾盐 | 35719-43-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙酰氨基苯酚钾盐
• 英文名称: potassium salt of 4-acetamidophenol
• 英文别名: potassium 4-acetamidophenoxide；potassium p-acetamidophenolate；potassium N-acetyl-p-aminophenate；Potassium 4-acetamidophenolate；potassium;4-acetamidophenolate
• CAS: 35719-43-8
• 化学式: C₈H₈NO₂*K
• 分子量: 189.255
• InChiKey: ONXCHMFMYVEUTI-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.28
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-乙酰氨基苯酚钾盐 在 铜 盐酸 作用下， 以 乙醇 为溶剂， 生成 4-硝基-4'-氨基二苯醚
  参考文献：
  名称：

  Photoinduced substitution. VIII. Effects of distant substituents on photoinduced aromatic substitution reactions

  摘要：

  DOI：

  10.1021/jo00827a004
• 作为产物：
  描述：

  对乙酰氨基酚 、 氢氧化钾 生成 4-乙酰氨基苯酚钾盐
  参考文献：
  名称：

  STEINBACH, J.;BEYER, G. -J.;GUNTHER, K., ZENTRALINST. KERNFORSCH. ROSSENDORF DRESDEN,(1989) N69, C. 27-28

  摘要：

  DOI：

文献信息

• Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines
  作者：Debra J. Trantolo、George E. Wright、Neal C. Brown

  DOI：10.1021/jm00155a016

  日期：1986.5

  examined in several series of N6-substituted 6-aminopyrimidines. The presence of alkyl groups as large as n-butyl in the 3-position of 6-(5-indanylamino)uracil had no effect on inhibitor-enzyme binding. Substituents in the 4-position of a series of 2-amino-6-(benzylamino)pyrimidines had complex effects: alkoxy and phenoxy derivatives were less active than the parent 4-oxo (isocytosine) compound, but alkylphenoxy

  在几个N6-取代的6-氨基嘧啶系列中，研究了对抑制枯草芽孢杆菌DNA聚合酶III的替代作用。在6-（5-茚满基氨基）尿嘧啶的3-位上存在与正丁基一样大的烷基对抑制剂-酶结合没有影响。一系列2-氨基-6-（苄氨基）嘧啶的4-位取代基具有复杂的作用：烷氧基和苯氧基衍生物的活性低于母体4-氧代（异胞嘧啶）化合物，而烷基苯氧基和卤代苯氧基衍生物的活性更高与4-苯氧基化合物本身相比，这表明在4-取代基和酶表面之间可以发生疏水结合，并且嘧啶环和pol III之间的空间可能代表了酶的活性位点。用甲基和乙基取代5-H大大降低了6-（苄氨基）-和6-对甲苯基尿嘧啶的抑制活性，但5-溴和5-碘类似物与母体化合物等价。这些结果表明，这些化合物的苯环必须以与嘧啶环平面垂直的构象存在，并且这种“活性构象”的电荷转移稳定性可能会补偿抑制剂中5个卤代基的空间位阻，酶复合物。
• Method for obtaining pioglitazone as an antidiabetic agent
  申请人：Halama Ales

  公开号：US20050043360A1

  公开（公告）日：2005-02-24

  A method for obtaining antidiabetic of formula (I), wherein the method comprises condensing of a 4-derivatized phenol or phenolate of general formula (II), wherein R is an amino group-containing organic residue, selected from the group comprising a residue of the following formula —NHR 3 , wherein R 3 is hydrogen or a protecting group, which is removed before further treatment, and a residue of general formula (A), wherein R b represents a carboxy group either in the free acid form or in the form of a salt or ester or another functional derivative or the nitrile group CN, and M represents a hydrogen or alkali metal atom, with a pyridine base of general formula (III, wherein Z is a leaving group other than a halogen, wherein, before or after carrying out the condensation, the following operations are carried out: (a) diazotizing the amino group present in organic residue R; (b) converting the diazotised residue R into a derivative of 2-halopropionate or 2-halopropionitrile of formula (B), wherein R b is as defined above and X is a halogen; (c) cyclizing the derivative of 2-halopropionate or 2-halopropionitrile with thiourea; (d) hydrolysing the resulting imine thus giving pioglitazone of formula (I).

  一种获得式(I)抗糖尿病药物的方法，其中该方法包括将通式(II)的4-取代酚或酚酸盐与通式(III)的吡啶碱缩合，其中R是含有氨基的有机残基，所选残基包括以下公式的残基：—NHR3，其中R3是氢或保护基，在进一步处理之前去除；以及通式(A)的残基，其中Rb表示自由酸形式或盐或酯或其他官能衍生物形式的羧基，或者是腈基CN，M表示氢或碱金属原子，Z表示离去基，不是卤素，缩合前或缩合后进行以下操作：(a)重氮化有机残基R中存在的氨基；(b)将重氮化的残基R转化为2-卤代丙酸酯或2-卤代丙腈的衍生物(B)，其中Rb如上定义，X为卤素；(c)与硫脲环化2-卤代丙酸酯或2-卤代丙腈的衍生物；(d)水解得到式(I)的吡格列酮。
• Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them
  申请人：INTERx RESEARCH CORPORATION

  公开号：EP0046270A1

  公开（公告）日：1982-02-24

  Novel transient prodrug forms of bio-affecting phenolic compounds are selected from the group consisting of those having the structural formula (I): wherein X is O, S or NR5 wherein R5 is hydrogen or lower alkyl; R1 is the mono- or polydehydroxylated residue of a non-steroidal bio-affecting phenol, with the proviso that R' is other than a monohydroxylated or didehydroxylated residue of a phenolic, nuclear dihydroxy natural sympathetic or sympathomimetic amine; R2 is selected from the group consisting of straight or branched chain alkyl, aryl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl, alkynylaryl, (lower acyloxy)alkyl, and carboxyalkyl; 3- to 8-membered, saturated or unsaturated mono-heterocyclic or polyheterocyclic containing from 1 to 3 of any one or more of the heteroatoms N, S or O; and mono- or polysubstituted derivatives of the above; R3 is hydrogen, lower acyl, cyano, halo(lower alkyl), carbamyl, lower alkylcarbamyl, di(lower alkyl)carbamyl, CH2ONO2, -CH2OCOR2 or any non-heterocyclic member of the group defined by R2 above; and n is at least one and equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol etherified via a R2COXCH(R3)0-moiety; those having the structural formula (II): wherein X, R', R2 and R3 are as defined above, and n and m are each at least one and the sum of n+m equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol either etherified via a R2COXCH(R3)0-moiety or esterified via a R2COO-moiety; and the pharmaceutically acceptable acid addition salts, quaternary ammonium salts and N-oxides thereof.

  生物效应酚类化合物的新型瞬效原药形式选自具有结构式(I)的化合物组成的组： 其中 X 是 O、S 或 NR5，其中 R5 是氢或低级烷基；R1 是非类固醇生物效应酚的单羟基或多羟基残基，但 R' 不是酚、核二羟基天然交感胺或拟交感胺的单羟基或双羟基残基；R2 选自直链或支链烷基、芳基、环烷基、烯基、环烯基、炔基、芳烷基、烷芳基、芳烯基、芳炔基、烯芳基、炔芳基、（低级酰氧基）烷基和羧基烷基组成的组；R3 是氢、低级酰基、氰基、卤代（低级烷基）、氨甲酰基、低级烷基氨甲酰 基、二（低级烷基）氨甲酰基、CH2ONO2、-CH2OCOR2 或上述 R2 定义的基团中的任何非杂环成员；且 n 至少为 1，等于通过 R2COXCH(R3)0 子代醚化的非甾体生物作用酚所包含的酚羟基官能团的总数；具有结构式（II）的酚羟基官能团： 其中 X、R'、R2 和 R3 如上文所定义，n 和 m 至少各为 1，且 n+m 之和等于非甾体类生物效应酚通过 R2COXCH(R3)0 子键醚化或通过 R2COO 子键酯化的酚羟基官能团的总数；及其药学上可接受的酸加成盐、季铵盐和 N-氧化物。
• Preparation of bis-(aminophenyl) ethers from (N-acetyl) aminophenols or their phenolates
  申请人：MALLINCKRODT, INC.(a Missouri corporation)

  公开号：EP0105660A1

  公开（公告）日：1984-04-18

  @ Bis-(aminophenyp ethers are prepared by effecting condensation reaction of an (N-acetyl)-aminophenol or the corresponding sodium or potassium (N-acetyl)-aminophenate with a halonitrobenzene under condensation reaction conditions to form an (N-acetyl)-aminophenyl nitrophenyl ether and hydrogenating the nitro group thereof under nitro- group hydrogenation conditions to form an (N-acetyl)-bis-(aminophenyl) ether. The latter compound is hydrolyzed with aqueous mineral acid under acid hydrolysis conditions to form an acidic aqueous dispersion of the bis-(aminophenyl) ether product, which can readily be recovered from the dispersion. Final bis-(aminophenyl) ether products thus prepared are typically of high purity and excellent colour properties, i.e., substantially colourless.

  在缩合反应条件下，(N-乙酰基)-氨基苯酚或相应的(N-乙酰基)-氨基苯酸钠或钾与卤化硝基苯发生缩合反应，生成(N-乙酰基)-氨基苯基硝基苯醚，并在硝基氢化条件下将其硝基氢化，生成(N-乙酰基)-双(氨基苯基)醚。后一种化合物在酸水解条件下与矿物酸水溶液进行水解，形成双（氨基苯基）醚产品的酸性水分散液，该分散液可以很容易地从分散液中回收。这样制备的最终双（氨基苯基）醚产品通常具有高纯度和极佳的颜色特性，即基本无色。
• Abuzar, Syed; Sharma, Satyavan; Gupta, Suman, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1984, vol. 23, # 12, p. 1274 - 1278
  作者：Abuzar, Syed、Sharma, Satyavan、Gupta, Suman、Misra, Anuradha、Katiyar, J. C.

  DOI：——

  日期：——